In a report released yesterday, Andrew Berens from Leerink Partners maintained a Hold rating on Boundless Bio Inc., with a price target of $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Hold rating due to a combination of factors related to Boundless Bio Inc.’s current developments and future prospects. The company has opened enrollment for the BBI-355 and BBI-825 combination arm in the POTENTIATE trial, with expected data in 2026, although no official guidance has been provided. This trial focuses on tumor types susceptible to synthetic lethality approaches and platinum-based chemotherapy agents. While Boundless Bio has generated clinical data for each agent individually, further progress was halted due to a narrow therapeutic window. The company is optimistic about the potential of a selective RNR inhibitor to enhance clinical response rates and improve the CHK1 therapeutic window, addressing limitations seen in prior trials that used non-selective RNR inhibitors.
Additionally, the BBI-940 program is targeting a previously undrugged kinesin, with an IND submission expected in the first half of 2026. Preclinical data for this program has shown promising results in terms of anti-proliferation and tumor regression. The company has reported having $127 million in cash, which is expected to support operations until the first half of 2028, with proof-of-concept clinical readouts anticipated within this timeframe. Berens’s Hold rating reflects the need for clinical validation of these new approaches before a more definitive investment recommendation can be made.
BOLD’s price has also changed dramatically for the past six months – from $2.180 to $1.110, which is a -49.08% drop .